<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04288050</url>
  </required_header>
  <id_info>
    <org_study_id>RECHMPL19_0586</org_study_id>
    <nct_id>NCT04288050</nct_id>
  </id_info>
  <brief_title>Evaluation of Glycemic Profiles in Diabetic Patients on Dialysis Under Insulin Balsal-bolus Protocol, Using Freestyle Libre</brief_title>
  <official_title>Evaluation of Glycemic Profiles in Diabetic Patients on Dialysis Under Insulin Balsal-bolus Protocol, Using Freestyle Libre. Observational Prospective Study Without Modification of Management.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In France, chronic end-stage renal disease affects more than 11,000 new patients each year&#xD;
      who will require dialysis or renal transplantation, of whom approximately 22.6% of new cases&#xD;
      are related to diabetes. Among them, about 94% are managed by hemodialysis (HD), the others&#xD;
      by peritoneal dialysis (PD). In addition, nearly 42% of dialysis patients have diabetes.&#xD;
      There are issues related to glycemic control during dialysis and specific to each dialysis&#xD;
      technique. Thus, hypoglycemic risk is the main risk observed during hemodialysis sessions,&#xD;
      linked in particular to the use of a 1g/L glucose free dialysate, a decrease in renal&#xD;
      neoglucogenesis and alterations in metabolic pathways. In addition, long-term glycemic&#xD;
      control is difficult to assess in dialysis patients, because of the limitations of HbA1c&#xD;
      witch is frequently underestimated.&#xD;
&#xD;
      This can be explained by 2 mechanisms:&#xD;
&#xD;
        -  EPO treatment is associated with an increase in the proportion of young Ã©rythrocytes&#xD;
&#xD;
        -  reduction in the lifetime of red blood cells reducing the duration of interaction&#xD;
           between glucose and hemoglobin.&#xD;
&#xD;
      The results of studies conducted using continuous glucose measurements over a short period of&#xD;
      time (48 hours to 5 days) suggest a benefit in using continuous glucose measurement to detect&#xD;
      glycemic fluctuations during dialysis. To our knowledge, no studies have been conducted to&#xD;
      evaluate longer-term glycemic control with this technology. In addition, the investigators&#xD;
      now have the Freestyle, which allows us to record the continuous measurement of interstitial&#xD;
      glucose over a longer period of time and is reimbursed for people on insulin basal-bolus&#xD;
      protocol.&#xD;
&#xD;
      Thus, the investigators propose an observational study to evaluate glycemic control during&#xD;
      dialysis sessions, but also to analyze the correlation between parameters measured with&#xD;
      Freestyle and HbA1c measured routinely, according to the follow-up recommendations in&#xD;
      diabetics.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Data : patient data (clinical, biological and additional examinations) on a database&#xD;
      registered at the University Hospital of Montpellier, on the secure server.&#xD;
&#xD;
        -  Computerized medical records (DXcare) and consultation letters.&#xD;
&#xD;
        -  Analysis of Freestyle data on a dedicated Freestyle View software, after downloading&#xD;
           data on this software&#xD;
&#xD;
      Demographic characteristics: Age, gender Clinical history: Older diabetes, presence of&#xD;
      diabetic retinopathy, diabetic maculopathy, microalbuminuria or proteinuria, older dialysis,&#xD;
      type of dialysis, presence of ischemic heart disease, history of stroke, arteriopathy,&#xD;
      gastroparesis, diabetic neuropathy, high blood pressure, hypercholesterolemia.&#xD;
&#xD;
      Treatments: diabetes, type of kidney replacement, other treatments&#xD;
&#xD;
      Biological assessment: Creatinemia, DFG, microalbuminuria, HbA1C, Hemoglobinemia, HDL, LDL,&#xD;
      triglyceridemia, cholesterol, albuminuria/creatinuria ratio, proteinuria/creatinuria ratio&#xD;
&#xD;
      Patients will sign a non-opposition form.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 16, 2020</start_date>
  <completion_date type="Actual">May 30, 2020</completion_date>
  <primary_completion_date type="Actual">May 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the time in range glycemic profile</measure>
    <time_frame>12 month</time_frame>
    <description>Evaluate the time in range glycemic profile in diabetic patients undergoing dialysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time above range of glycemic target</measure>
    <time_frame>6 month</time_frame>
    <description>Time above range of glycemic target</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time below range of glycemic target</measure>
    <time_frame>6 month</time_frame>
    <description>Time below range of glycemic target</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose management Indicator</measure>
    <time_frame>6 month</time_frame>
    <description>Glucose management Indicator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hypoglycemic events</measure>
    <time_frame>6 month</time_frame>
    <description>Number of hypoglycemic events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean number of scans on diabetic subjects in Dialysis.</measure>
    <time_frame>6 month</time_frame>
    <description>mean number of scans on diabetic subjects in Dialysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the Delta between measured HbA1c and GMI.</measure>
    <time_frame>6 month</time_frame>
    <description>Evaluate the Delta between measured HbA1c and GMI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the correlation between average interstitial glucose measured at Freestyle and measured HbA1c.</measure>
    <time_frame>6 month</time_frame>
    <description>Evaluate the correlation between average interstitial glucose measured at Freestyle and measured HbA1c.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">80</enrollment>
  <condition>Diabetic</condition>
  <arm_group>
    <arm_group_label>Diabetic subjects under dialysis</arm_group_label>
    <description>Diabetic subjects under dialysis</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Diabetic patients with dialysis&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Subjects over 18 years of age&#xD;
&#xD;
          -  dialysis patients&#xD;
&#xD;
          -  diabetics (any diabetes)&#xD;
&#xD;
          -  any anti-diabetic treatment&#xD;
&#xD;
          -  no objection form&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Objection of the subject&#xD;
&#xD;
          -  Subject under guardianship or tutelage&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ariane SULTAN, PR</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital, Montpellier</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Uhmontpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>December 4, 2019</study_first_submitted>
  <study_first_submitted_qc>February 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 27, 2020</study_first_posted>
  <last_update_submitted>June 4, 2020</last_update_submitted>
  <last_update_submitted_qc>June 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>continuous glucose monitoring system</keyword>
  <keyword>haemodialysis</keyword>
  <keyword>peritoneal dialysis</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>NC</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

